Literature DB >> 28417239

Incidental Gallbladder Cancer: Residual Cancer Discovered at Oncologic Extended Resection Determines Outcome: A Report from High- and Low-Incidence Countries.

Eduardo Vinuela1,2, Eduardo A Vega1,3, Suguru Yamashita3, Marcel Sanhueza1,2, Rosemarie Mege1,2, Gabriel Cavada4, Thomas A Aloia3, Yun Shin Chun3, Jeffrey E Lee3, Jean-Nicolas Vauthey3, Claudius Conrad5.   

Abstract

BACKGROUND: Gallbladder cancer detected incidentally after cholecystectomy (IGBC) currently is the most common diagnosis of gallbladder cancer, and oncologic extended resection (OER) is recommended for tumors classified higher than T1b. However, the precise prognostic significance of residual cancer (RC) found at the time of OER has not been well established. This analysis aimed to determine the prognostic impact of RC found in patients with IGBC undergoing OER.
METHODS: Outcomes for IGBC at a center for a low-incidence country (USA) and a high-incidence country (Chile) between January 1999 and June 2015 were analyzed. Residual cancer was defined as histologically proven cancer at OER. Predictors of disease-specific survival (DSS) were analyzed.
RESULTS: Of 187 patients, 171 (91.4%) achieved complete resection (R0) at OER. The rates of surgical mortality and severe morbidity were respectively 1.1 and 9.6%. Of the 187 patients, 73 (39%) had RC. Perineural invasion and/or lymphovascular invasion and T3 stage were associated with the presence of RC. In both countries, RC was associated with a significantly shorter median survival (23% vs not reached; p < 0.001) and lower 5-year DSS rate (19% vs. 74%; p < 0.001) despite R0 resection. In the multivariable analysis, RC was an independent poor predictor of DSS (hazard ratio [HR], 4.00; 95% confidence interval [CI], 2.13-7.47; p < 0.001), as were lymphovascular and/or perineural invasion (HR, 1.95; 95% CI, 1.19-3.21; p = 0.008).
CONCLUSIONS: The presence of RC in patients undergoing OER for IGBC is associated with poor DSS in both high- and low-incidence countries, even when R0 resection is achieved. Residual cancer defines a high-risk cohort for whom adjuvant therapy may be beneficial.

Entities:  

Mesh:

Year:  2017        PMID: 28417239     DOI: 10.1245/s10434-017-5859-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status.

Authors:  Eduardo A Vega; Eduardo Vinuela; Suguru Yamashita; Marcel Sanhueza; Gabriel Cavada; Cristian Diaz; Thomas A Aloia; Yun Shin Chun; Ching-Wei D Tzeng; Masayuki Okuno; Claire Goumard; Jean-Nicolas Vauthey; Jeffrey E Lee; Claudius Conrad
Journal:  J Gastrointest Surg       Date:  2017-07-27       Impact factor: 3.452

2.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

3.  Port-site metastasis of unsuspected gallbladder carcinoma with ossification after laparoscopic cholecystectomy: A case report.

Authors:  Kai-Jun Gao; Zhi-Long Yan; Yu Yu; Liang-Qi Guo; Chen Hang; Jia-Bin Yang; Mou-Cheng Zhang
Journal:  World J Clin Cases       Date:  2020-11-26       Impact factor: 1.337

4.  A Comparison Between the Prognosis of Simultaneous and Salvage Radical Resection in Incidental Gallbladder Cancer.

Authors:  Shilin He; Tunan Yu; Parikshit Asutosh Khadaroo; Liuxin Cai; Yeyuan Chu; Fangqiang Wei; Xiao Liang
Journal:  Cancer Manag Res       Date:  2020-12-30       Impact factor: 3.989

5.  Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center Retrospective Analysis.

Authors:  Rahul Rahul; Kulbhushan Haldenia; Ashish Singh; Vishwas Kapoor; Rajneesh K Singh; Rajan Saxena
Journal:  Cureus       Date:  2022-07-08

Review 6.  Treatment of Resectable Gallbladder Cancer.

Authors:  Eduardo A Vega; Sebastian Mellado; Omid Salehi; Richard Freeman; Claudius Conrad
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.